USP22 and acute promyelocytic leukemia: Since USP22 acts in highly context- and tumor-specific manners, our findings might open novel therapeutic opportunities to re-sensitize ATRA-resistant, relapsed APL patients to ATRA treatment by simultaneous inhibition of USP22.